BiotechTube
Azome Therapeutics

Azome Therapeutics

San Diego, United States· Est.
azometherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Azome Therapeutics is a private, preclinical-stage biotech targeting the NLRP3 inflammasome with a novel, upstream approach via its lead candidate AZM-152. The company is initially pursuing severe inflammatory pulmonary diseases with high unmet need, such as ARDS, BPD, and IPF exacerbations. A key recent milestone is a CRADA with the National Center for Advancing Translational Sciences to advance AZM-152 for BPD prevention. Azome represents a specialized player in the competitive inflammasome space, with a strategy focused on intercepting the pathway before full activation.

PulmonologyImmunologyCritical Care

Technology Platform

A drug discovery platform focused on developing selective antagonists of the NLRP3 inflammasome, with a novel approach targeting upstream priming signals via RHAMM (Receptor for Hyaluronan-Mediated Motility) inhibition.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The significant unmet need in severe inflammatory lung diseases like ARDS and BPD, where no targeted pharmacologic therapies exist, presents a major commercial opportunity.
An upstream inhibition strategy could offer a differentiated safety and efficacy profile.
Success in a niche indication like BPD could provide a rapid regulatory pathway and proof-of-concept for broader applications.

Risk Factors

The novel RHAMM-targeting mechanism is unproven in humans, carrying high clinical development risk.
The company faces intense competition from well-funded players developing direct NLRP3 inhibitors.
As a small, private, pre-revenue biotech, Azome is vulnerable to financing risks and potential dilution.

Competitive Landscape

The NLRP3 inhibitor space is competitive, with several biotech (e.g., NodThera, Ventus) and large pharma (e.g., Roche via Inflazome acquisition) companies advancing direct NLRP3 inhibitors into clinical trials for inflammatory diseases. Azome's differentiation lies in its upstream, priming-focused approach via RHAMM, but it trails these competitors in clinical development stage.

More companies in Small Molecule Drugs →More companies in United States →